# bioAffinity Technologies, Inc. (BIAF) · Edgar & Edgarette company card

> bioAffinity Technologies (BIAF) saw revenue fall 34.2% in FY2025 to $6 million, operating margin -172% against a 14.9% median for commercial physical & biological research, equity 66.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1712762 · fiscal year ended 2025-12-31 · 4 audited years read · [page](https://www.pops4.com/boards/company/BIAF) · [JSON](https://www.pops4.com/boards/company/BIAF.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $6M |
| Revenue growth, 1 year | -34.2% |
| Revenue growth per year | -3.7% |
| Operating margin | -171.6% (prior year -95.6%) |
| Net margin | -242.0% |
| Operating cash flow | −$9M |
| Capital spending | $60,568 |
| Free cash flow | −$9M |
| Cash | $6M |
| Long-term debt | — |
| Total assets | $11M |
| Total equity | $7M |
| Equity ÷ assets | 66.4% |
| Return on equity | -204.9% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -22.01 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -171.6% in FY2025; revenue is hard to predict: its 80% range is ±54%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $6.2M (FY2025). Experience: revenue down 34.2% on the year, down 3.7% a year over 3 years; operating margin -171.6%, down from -95.6%. Soundness: equity 66.4% of assets, return on equity -204.9%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $2.7M and $9.0M next year (method v4.1: its own 3-year record of growth weighed at 40% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $2.5M to $9.8M. A statistical range, not company guidance. Against peers (8 filers, $50M+ revenue, its industry group): operating margin -171.6% against a 14.9% median; growth -34.2% against 5.2%.

Range logged 2026-09-29, receipt 467da6c6ca12136f, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-07-31 ([filing](https://www.sec.gov/Archives/edgar/data/1712762/000149315226035672/0001493152-26-035672-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-04-30 ([filing](https://www.sec.gov/Archives/edgar/data/1712762/000149315226020591/0001493152-26-020591-index.htm))

## Recent filings

- 8-K · filed 2026-10-29 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1712762/000149315226049188/0001493152-26-049188-index.htm)
- DEF 14A · filed 2026-10-23 · [filing](https://www.sec.gov/Archives/edgar/data/1712762/000149315226048245/0001493152-26-048245-index.htm)
- 8-K · filed 2026-10-15 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1712762/000149315226047168/0001493152-26-047168-index.htm)
- 8-K · filed 2026-10-13 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1712762/000149315226046755/0001493152-26-046755-index.htm)
- 8-K · filed 2026-10-09 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1712762/000149315226046548/0001493152-26-046548-index.htm)
- 8-K · filed 2026-10-08 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1712762/000149315226046266/0001493152-26-046266-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001712762.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1712762

## Cite

POPS4, Edgar & Edgarette: bioAffinity Technologies, Inc. (BIAF) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/BIAF. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.